RETRACTED ARTICLE: A NEW THREE-DIMENSIONAL Co(II)-MIXED-LIGAND MOF: A PROTECTIVE
EFFECT AGAINST ACUTE CEREBRAL INFARCTION BY REDUCING THE HS-CRP CONTENT AND INFLAMMATORY
RESPONSE

Xu, Jing; Li, P; He, Bin; Gu, Hongbin; Zhuang, Jianhua; Peng, Hao

doi:10.1134/s0022476620070173

Cited by 4 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several research have concentrated on the design of MOFs‐based nanoparticles for scavenging ROS and reducing proinflammatory cytokines. [ 138a,141,142,154 ] For example, He et al. synthesized a kind of bioactive ZIF‐8‐capped ceria nanoparticles (CeO 2 @ZIF‐8 NPs) by a simple in situ synthetic strategy to obtain increased catalytic and antioxidative properties, and thereby enhance antistroke therapeutic efficacy.…”

Section: Mofs In Treatment Of Neurological Diseasesmentioning

confidence: 99%

“…In another study, a new Co(II)‐based MOF, {[Co 2 (TCPP)(BPY)](DMF) 3 } n , based on 2,3,5,6‐tetrakis(4‐carboxyphenyl)pyrazine (H 4 TCPP) and 4,4′‐bipyridine (BPY), was fabricated for neuroprotective therapy of the acute cerebral ischemic in rat model. [ 141 ] The results showed that the infarct area of the brain was considerably decreased after treatment of the Co(II)‐based MOF for 2 weeks. The contents of inflammatory cytokine such as TNF‐α, IL‐1β, hs‐CRP and in the serum were apparently inhibited after therapy of the MOF‐based nanomaterial.…”

Section: Mofs In Treatment Of Neurological Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Metal–Organic Frameworks‐Based Nanoplatforms for the Theranostic Applications of Neurological Diseases

Niu

Zhao

et al. 2023

Small

View full text Add to dashboard Cite

Neurological diseases are the foremost cause of disability and the second leading cause of death worldwide. Owing to the special microenvironment of neural tissues and biological characteristics of neural cells, a considerable number of neurological disorders are currently incurable. In the past few years, the development of nanoplatforms based on metal–organic frameworks (MOFs) has broadened opportunities for offering sensitive diagnosis/monitoring and effective therapy of neurology‐related diseases. In this article, the obstacles for neurotherapeutics, including delayed diagnosis and misdiagnosis, the existence of blood brain barrier (BBB), off‐target treatment, irrepressible inflammatory storm/oxidative stress, and irreversible nerve cell death are summarized. Correspondingly, MOFs‐based diagnostic/monitoring strategies such as neuroimaging and biosensors (electrochemistry, fluorometry, colorimetry, electrochemiluminescence, etc.) and MOFs‐based therapeutic strategies including higher BBB permeability, targeting specific lesion sites, attenuation of neuroinflammation/oxidative stress as well as regeneration of nerve cells, are extensively highlighted for the management of neurological diseases. Finally, the challenges of the present research from perspective of clinical translation are discussed, hoping to facilitate interdisciplinary studies at the intersections between MOFs‐based nanoplatforms and neurotheranostics.

show abstract

Section: Mofs In Treatment Of Neurological Diseasesmentioning

confidence: 99%

Section: Mofs In Treatment Of Neurological Diseasesmentioning

confidence: 99%

Metal–Organic Frameworks‐Based Nanoplatforms for the Theranostic Applications of Neurological Diseases

Niu

Zhao

et al. 2023

Small

View full text Add to dashboard Cite

show abstract

“…After the occurrence of cerebral infarction(CI), the blood supply to corresponding brain tissues is affected, which leads to ischemia and hypoxia of brain tissues and then denaturation and necrosis, thereby causing damage to brain tissues and neurological functions, and directly affecting the body’s limb motor function. 3 Relaxing blocked cerebral vessels, restoring the blood supply to brain tissues, as well as protecting brain tissues and neurological functions are the main measures for ACI treatment. Tirofiban is a new clinical antiplatelet drug, which can quickly inhibit platelet aggregation, and has important value in dredging blocked vessels and opening the microcirculation.…”

Section: Introductionmentioning

confidence: 99%

Clinical study of Edaravone Dexborneol combined with Tirofiban in treatment of Acute Cerebral Infarction

Mi,

Hou,

Liu

et al. 2023

Pak J Med Sci

View full text Add to dashboard Cite

Objective: To explore the clinical efficacy and safety of edaravone dexborneol combined with tirofiban in the treatment of acute cerebral infarction. Methods: This is a retrospective study. A total of 80 patients with acute cerebral infarction (ACI) treated in Cangzhou People’s Hospital from March 2018 to December 2021 were selected, and randomly divided into the routine group(n=40) and intervention group(n=40) according to the principle of random draw. Neurological deficits in the two groups were evaluated and compared before and after treatment using the National Institutes of Health Stroke Scale (NIHSS). The quality of life of the patients was evaluated by the modified Rankin Scale (mRS). Results: Before treatment, NIHSS and mRS scores of the two groups were not statistically significant(p>0.05); the levels of Vmin and Qmin in the two groups showed no statistical significance(p>0.05); no statistical significance was found in CRP or IL-6 levels between the two groups(p>0.05). After treatment for 14 days, the NIHSS and mRS scores of the two groups both decreased, which was more significant in the intervention group(p<0.05); Vmin and Qmin levels increased in both groups, which was more obvious in the intervention group(p<0.05); CRP and IL-6 levels reduced in both groups, which was more remarkable in the intervention group(p<0.05). The incidences of relevant adverse drug reactions presented no differences between the two groups during treatment(p>0.05). Conclusion: Edaravone dexborneol combined with tirofiban in the treatment of ACI can effectively improve patients’ neurological deficits, quality of life and cerebral blood flow, and reduce inflammatory factor levels, have significant clinical efficacy and high clinical treatment safety. doi: https://doi.org/10.12669/pjms.40.1.7630 How to cite this: Mi Y, Hou Z, Liu J, Zhang C. Clinical study of Edaravone Dexborneol combined with Tirofiban in treatment of Acute Cerebral Infarction. Pak J Med Sci. 2024;40(1):---------. doi: https://doi.org/10.12669/pjms.40.1.7630 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

The mixed-ligand strategy for structural modification of MOF materials to enhance the photocatalytic degradation and adsorption of organic pollutants: A review

Faaizatunnisa,

Ediati,

Yusof

et al. 2024

Nano-Structures & Nano-Objects

View full text Add to dashboard Cite

RETRACTED ARTICLE: A NEW THREE-DIMENSIONAL Co(II)-MIXED-LIGAND MOF: A PROTECTIVE EFFECT AGAINST ACUTE CEREBRAL INFARCTION BY REDUCING THE HS-CRP CONTENT AND INFLAMMATORY RESPONSE

Cited by 4 publications

References 16 publications

Metal–Organic Frameworks‐Based Nanoplatforms for the Theranostic Applications of Neurological Diseases

Metal–Organic Frameworks‐Based Nanoplatforms for the Theranostic Applications of Neurological Diseases

Clinical study of Edaravone Dexborneol combined with Tirofiban in treatment of Acute Cerebral Infarction

The mixed-ligand strategy for structural modification of MOF materials to enhance the photocatalytic degradation and adsorption of organic pollutants: A review

Contact Info

Product

Resources

About